Compare Allbirds Inc (BIRD) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Davita Inc — how do they compare? Allbirds Inc trades at $2.6 (market cap $22.68M), while Davita Inc trades at $179.02 (market cap $11.72B). The key difference: Davita Inc is far larger — about 516.8× Allbirds Inc's market cap, and Davita Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| BIRD | DVA | |
|---|---|---|
Market Cap | $22.68M | $11.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $240.96 |
52-Week Low | $2.21 | $103.87 |
Enterprise Value | $41.54M | $24.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD (Smartbird) trades at $2.53, up 5.42% with a bullish technical signal despite mixed earnings. The company completed a strategic pivot from footwear to AI infrastructure in June 2026, appointing former AWS executive Nadia Carlsten as CEO. While revenue declined to $152M in 2025 with a -53.4% net margin, the P/S ratio of 0.15 suggests potential undervaluation relative to AI sector peers.
The outlook hinges on successful execution of the AI infrastructure strategy, though significant execution risks remain given negative cash flows and lack of profitability. Analyst consensus shows cautious optimism with 21% buy ratings amid high institutional hold positions. Near-term catalysts include new board appointments and AI business development progress.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
